0000891293-18-000086.txt : 20180920 0000891293-18-000086.hdr.sgml : 20180920 20180920164605 ACCESSION NUMBER: 0000891293-18-000086 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180918 FILED AS OF DATE: 20180920 DATE AS OF CHANGE: 20180920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Craig Adam R CENTRAL INDEX KEY: 0001339498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 181079858 MAIL ADDRESS: STREET 1: C/O INNOVIVE PHARMACEUTICALS, INC. STREET 2: 555 MADISON AVENUE, 25TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2018-09-18 0 0000891293 CTI BIOPHARMA CORP ctic 0001339498 Craig Adam R 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 1 1 0 0 President and CEO Non-Qualified Stock Option (right to buy) 1.88 2018-09-18 4 A 0 600000 0 A 2028-09-18 Common Stock 600000 600000 D The stock options will vest in six equal semi-annual installments over a three-year period commencing on September 18, 2018 subject to continued employment with the Company through the applicable vesting dates, such that the option will be fully vested on September 18, 2021. Bruce J. Seeley, Attorney-in-fact For: Adam R. Craig 2018-09-20